Faricimab eye injections and kidney function in diabetes

This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.

This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.

This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.

This trial tests a higher dose of aflibercept (8 mg) for people whose diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization has not improved with standard treatment. The goal is to see if this stronger dose can reduce fluid and improve vision.

This trial tests a new eye injection called faricimab to treat diabetic macular edema (swelling in the back of the eye) in South Asian patients. The goal is to see how well it works, how long the effects last, and if it is safe.

This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.